Your session is about to expire
← Back to Search
Diagnostic Test
Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1
N/A
Waitlist Available
Led By Miriam Bornhorst, MD
Research Sponsored by Children's National Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3-4 years
Awards & highlights
No Placebo-Only Group
Summary
This study is being conducted to determine if Whole Body MRI (WBMRI) can be used to identify Atypical Neurofibromas (ANF) in Neurofibromatosis Type 1 (NF1) patients with high tumor burden. Each enrolled participant will have two (2) WBMRIs without sedation during the study period. Eligible participants must be Male or Female between the ages of 8-30 with diagnosed NF1; with one or more PN greater than 3cm in diameter and willing to comply with study procedures.
Eligible Conditions
- Benign Tumors
- Neurofibromatosis
- Plexiform Neurofibroma
- Neurofibroma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3-4 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3-4 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
To determine if WBMRI can be used to identify ANF in NF1 patients with high tumor burden.
Secondary study objectives
Determine if clinical signs and symptoms correlate with tumor burden and/or the presence of ANF on WBMRI
Other study objectives
Determine if the cfDNA levels correlate with presence of ANF.
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Study ArmExperimental Treatment1 Intervention
Whole Body MRI along with standard of care regional MRI and blood draw at enrollment followed by Whole Body MRI along with standard of care regional MRI and blood draw after 4-6 months.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Whole Body MRI
2007
N/A
~40
Find a Location
Who is running the clinical trial?
Children's National Research InstituteLead Sponsor
221 Previous Clinical Trials
258,360 Total Patients Enrolled
Miriam Bornhorst, MDPrincipal InvestigatorChildren's National Health System
1 Previous Clinical Trials